trending Market Intelligence /marketintelligence/en/news-insights/trending/-j2iJaT9N6K6dckCuQ6l9g2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Teva loses Copaxone patent appeal in a win for Mylan, Novartis generics

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Teva loses Copaxone patent appeal in a win for Mylan, Novartis generics

Israel's Teva Pharmaceutical Industries Ltd. lost an appeal to regain four patents on its blockbuster multiple sclerosis drug Copaxone, reaffirming marketability of generics from Mylan NV and Novartis AG generics unit Sandoz.

The U.S. Court of Appeals for the Federal Circuit on Oct. 12 upheld a January 2017 decision by a District Court judge that said the patents on Copaxone's 40-milligram-per-milliliter dose were invalid.

Mylan launched the first Copaxone generic in October 2017, called Glatiramer Acetate Injection, followed by Novartis' Glatopa. Copaxone had sales of $4.2 billion in 2016, which fell to $3.8 billion in 2017, according to Teva's recent financial reports. Although the company retained an 85% market share halfway through 2018, sales have dwindled over the course of the year, and the branded drug is expected to post sales of about $1.8 billion for 2018.

The U.S. District Court for the District of Delaware, in deciding the original case, ruled that it was reasonable to believe generics makers could have created the product on their own, invalidating Teva's patents.

"Here, there was market pressure to solve a known problem — the fact that many MS patients could not tolerate daily injections," the District Court ruled. "And there were a finite number of predictable solutions that a person of ordinary skill in the art would have good reason to pursue."

Copaxone and its generics are designed to be injected three times per week, a regimen that improved upon daily injections for patients with multiple sclerosis and led to its blockbuster status.

The loss lends added importance to Teva's other prospects, including its newly U.S. Food and Drug Administration-approved migraine treatment Ajovy, which will go head-to-head against rivals Aimovig from Amgen Inc. and Emgality from Eli Lilly and Co.